Quotient Limited Announces Second Quarter Fiscal 2023 Business Update (10-Q)

We are thrilled to announce a transformative milestone in our journey—a comprehensive rebranding effort aimed at better reflecting the company’s mission, values, and vision for the future.

We recently announced that the new ALBA Elution Kit was CE marked. We are delighted to say it is now also FDA registered! The ALBA Elution Kit for the acid elution of antibodies from intact red cells produces 10 elutions

We are pleased to announce that Alba by Quotient continues to grow in Europe. It is now also available in the Czech Republic. Here are the geographies where Alba by Quotient is available: Alba by Quotient believes in creating value

We are delighted to announce that the new ALBA Elution Kit is now CE marked and will soon be available.  The ALBA Elution Kit for the acid elution of antibodies from intact red cells produces 10 elutions per kit, delivers

We are excited to announce that our abstract, titled “Performance characteristics of a new, fully automated planar microarray immunoassay for the detection of autoantibodies against Centromere Protein B and correlations with autoimmune disease diagnosis” will be presented at the 2023

Quotient and FAS Diagnostic Group, Inc. have signed a distribution agreement, which will enable FAS Diagnostic Group, Inc. to distribute Alba by Quotient® and MosaiQ® in the Philippines, Southeast Asia. The distribution agreement takes effect immediately.This strategic partnership reaffirms Quotient’s commitment